Description

Eterna Peptides presents premium-grade Klow Blend lyophilized powder, an advanced multi-peptide formulation engineered to study maximum tissue remodeling, accelerated cellular recovery, and profound anti-inflammatory pathways. Combining four high-purity synthetic peptide chains—GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg)—in a single ultra-concentrated vial, this synergistic matrix serves as an elite investigative tool for tracking concurrent growth factor upregulation, structural protein synthesis, and cytoprotective mechanisms.

### Advanced 80mg Synergistic Peptide Profile
Each carefully calibrated vial delivers an 80mg total active compound distribution:
* **GHK-Cu (50mg – Copper Peptide):** A highly purified copper-binding tripeptide extensively studied for its ability to upregulate collagen, elastin, and glycosaminoglycan (GAG) gene signaling in structural fibroblasts, reversing cellular degradation models.
* **BPC-157 (10mg – Body Protection Compound):** A stable synthetic pentadecapeptide investigated for its profound gastric and systemic cytoprotective properties, localized expression of growth factor receptors (such as VEGFR2), and accelerated soft tissue healing kinetics.
* **TB-500 (10mg – Thymosin Beta-4 fragment):** A low-molecular-weight acetylated peptide that binds tightly to G-actin. It is actively researched for its role in promoting high-velocity cell migration, actin polymerization, and rapid microvascular network branching (angiogenesis).
* **KPV (10mg – Lysine-Proline-Valine):** A naturally modeled tripeptide tracking advanced cellular immunomodulation. KPV is studied for its ability to downregulate NF-kB signaling pathways, suppressing pro-inflammatory cytokine expression to minimize oxidative and tissue-level trauma.

### Mechanism of Action
The Klow multi-peptide matrix targets overlapping biological cascades to explore optimal systemic repair:
* **Extracellular Matrix Recouping:** GHK-Cu and BPC-157 work concurrently to stimulate structural fibroblasts, optimizing tissue density and driving smooth cellular re-epithelialization.
* **Angiogenesis Signaling:** Preclinical models indicate that BPC-157 and TB-500 synergize to promote vascular endothelial growth factor (VEGF) signaling, coordinating new capillary structures to improve localized microvascular perfusion.
* **Inflammatory Cascade Attenuation:** KPV and BPC-157 actively suppress chronic inflammatory signaling pathways, neutralizing cellular stress to shield fragile, recovering tissue boundaries.

### Research Applications
In preclinical and in vitro laboratory models, the Klow Blend is utilized to investigate:
* High-velocity soft tissue wound healing, myofibrillar protein cross-linking, and structural scar remodeling.
* Advanced dermatological cell repair, extracellular matrix restructuring, and localized dermal density optimization.
* Structural connective tissue repair, tendon/ligament remodeling, and musculoskeletal baseline recovery.
* Multi-pathway receptor saturation where copper transport, growth factor signaling, actin migration, and cytokine suppression intersect.

Our Klow Blend vials undergo strict laboratory quality control guidelines to ensure an exact 50:10:10:10 mass ratio, absolute structural purity, and dependable experimental reproducibility.

—
*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*